matdesign24/iStock via Getty Images Listen here or on the go via Apple Podcasts and Spotify Steve Cress, our Head of Quant, reviews the investing year that was (1:20). Past returns of Steve's previous stock picks (11:50). Reviewing the top 10 stocks for 2025, which returned 45.6% vs S&P 500's 17.6%, (14:50). This is an excerpt from a recent webinar, Top 10 Stocks For 2025 -- Recap & Results. Transcript Daniel Snyder: Hey, everyone, Daniel Snyder here from Seeking Alpha. Thank you so much for join ...

I last covered Argan ( AGX ) in September with a buy rating, and the stock is up ~60% since then. The stock has given up some of the gains in the recent weeks, especially postI have over 15 years of experience investing and have provided research services to mid-sized hedge funds with assets under management between $100 and $500 million. I also have had a brief stint as a sell-side analyst. I am now focusing primarily on managing my own money and my purpose here is to share my views and benefit from the in ...

Group 1 - The stock of Argan (AGX) has increased approximately 60% since the last coverage in September, although it has recently given up some gains [1] - The analyst has over 15 years of experience in investment and has provided research services to mid-sized hedge funds with assets under management between $100 million and $500 million [1] - The investment strategy focuses on medium-term investing in ideas with catalysts for value unlocking or short selling in case of downside catalysts, with a preference for growth stories at reasonable prices [1] Group 2 - The analyst has a generalist approach but has primarily analyzed the industrial, consumer, and technology sectors, where higher conviction in investments is typically found [1]

Core Insights - Roche's experimental oral drug giredestrant has demonstrated a 30% reduction in the risk of breast cancer recurrence compared to standard endocrine therapy, marking a significant advancement in treatment options [1] Company Summary - Roche is advancing its portfolio in oncology with giredestrant, which is positioned as a potential alternative to existing therapies [1] Industry Summary - The development of giredestrant represents a notable shift in breast cancer treatment paradigms, potentially impacting market dynamics and patient outcomes in the oncology sector [1]

I focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-term. Ultimately, I aim to identify companies with solid fundamentals, sustainable competitive advantages, and growth potential.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the compa ...

I focus on long-term investments while incorporating short-term shorts to uncover alpha opportunities. My investment approach revolves around bottom-up analysis, delving into the fundamental strengths and weaknesses of individual companies. My investment duration is the medium to long-term. Ultimately, I aim to identify companies with solid fundamentals, sustainable competitive advantages, and growth potential.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the compa ...

As a finance enthusiast with experience in research, I am deeply engaged in studying diverse businesses, especially in the technology, industrial, and conglomerate sectors. I really like companies that have strong foundations and see them doing well in the long run. I enjoy writing about these businesses, telling their stories, strategies, and financial details. I use a mix of looking at their finances and writing to give insights into how well companies might do, helping people understand the market better ...

As a finance enthusiast with experience in research, I am deeply engaged in studying diverse businesses, especially in the technology, industrial, and conglomerate sectors. I really like companies that have strong foundations and see them doing well in the long run. I enjoy writing about these businesses, telling their stories, strategies, and financial details. I use a mix of looking at their finances and writing to give insights into how well companies might do, helping people understand the market better ...

With years of investing experience in the financial markets, I have honed my skills in identifying and capitalizing on investment opportunities across diverse sectors. My investment approach is based on fundamental analysis of stocks, focusing on companies with a strong competitive moat, consistent growth in free cash flow, and a track record of robust financial performance.My investment philosophy is rooted in long-term, fundamental investing. I steer clear of short-term trading tactics and options, believ ...

Core Insights - The article emphasizes a long-term investment philosophy focused on fundamental analysis, targeting companies with strong competitive advantages and consistent free cash flow growth [1]. Group 1: Investment Philosophy - The investment approach is centered on identifying undervalued stocks with growth potential and avoiding overvalued stocks [1]. - The analyst believes in the power of long-term investing over short-term trading tactics, which has proven effective in navigating market complexities [1]. Group 2: Professional Background - The analyst has a background in business and economics, providing a solid foundation for investment analysis [1]. - Currently, the analyst is associated with a local brokerage firm and contributes to Seeking Alpha, aiming to share analytical insights with the investment community [1].